In accordance with the results of ADR evaluation, to further protect drug safety for the people, NMPA issued an Announcement on June 9, 2020, with decisions made to uniformly revise the [adverse reactions], [contraindications] and [precautions] in the package inserts of Chuanbei Pipa Preparations (including syrups, ointments, granules, tablets and capsules).